Including Patient Information, for additional Important Safety Information. Please see the full Prescribing Information, You may report side effects to the FDA at (800) FDA-1088 or You may also report side effects to MORPHOSYS US INC. Ongoing study to confirm the clinical benefit of MONJUVI.Ĭall your doctor for medical advice about side effects. The approval of MONJUVI is based on a type of response rate. MONJUVI (tafasitamab-cxix) is a prescription medicine given with lenalidomide to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory) and who cannot receive a stem cell transplant. Tell your healthcare provider about all the medications you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. You should also read the lenalidomide Medication Guide for important information about pregnancy, contraception, and blood and sperm donation. Do not breastfeed during treatment and for at least 3 months after your last dose of MONJUVI It is not known if MONJUVI passes into your breastmilk. Are breastfeeding or plan to breastfeed.Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with MONJUVI.You should use an effective method of birth control (contraception) during treatment and for at least 3 months after your last dose of MONJUVI.Do not receive treatment with MONJUVI in combination with lenalidomide if you are pregnant because lenalidomide can cause birth defects and death of your unborn baby You should not become pregnant during treatment with MONJUVI. Are pregnant or plan to become pregnant.Have an active infection or have had one recently.Your healthcare provider may need to delay or completely stop treatment with MONJUVI if you have severe side effects.īefore you receive MONJUVI, tell your healthcare provider about all your medical conditions, including if you If you do not have any reactions, your healthcare provider may decide that you do not need these medicines with later infusions. Your healthcare provider will give you medicines before each infusion to decrease your chance of infusion reactions. These are not all the possible side effects of MONJUVI. The most common side effects of MONJUVI include Tell your healthcare provider right away if you get a fever of 100.4 ☏ (38 ☌) or above, or develop any signs or symptoms of an infection Serious infections, including infections that can cause death, have happened in people during treatment with MONJUVI and after the last dose. Tell your healthcare provider right away if you get a fever of 100.4 ☏ (38 ☌) or above, or any bruising or bleeding Your healthcare provider will monitor your blood counts during treatment with MONJUVI. Low blood cell counts are common with MONJUVI, but can also be serious or severe. Low blood cell counts (platelets, red blood cells, and white blood cells). Tell your healthcare provider right away if you get fever, chills, flushing, headache, or shortness of breath during an infusion of MONJUVI Your healthcare provider will monitor you for infusion reactions during your infusion of MONJUVI. MONJUVI may cause serious side effects, including IMPORTANT SAFETY INFORMATION What are the possible side effects of MONJUVI? Learn about how MONJUVI was studied and see the results from a clinical trial. It includes details about how treatment may help you, how you can receive MONJUVI, the side effects you may experience, and support options for you during your treatment. This website provides important information about what to expect during treatment with MONJUVI. Seeking more information about MONJUVI for yourself or a loved one. You and your healthcare team may be considering whether to begin your treatment with MONJUVI. What to expect from treatment with MONJUVI There is an ongoing study to confirm the clinical benefit of MONJUVI. It is not known if MONJUVI is safe and effective in children. Lymphoma (DLBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory) and who MONJUVI (tafasitamab-cxix) is a prescription medicine given with lenalidomide to treat adults with certain types of diffuse large
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |